































What we can learn from longevity mutants 
 
The reason why we age seems obvious: entropy 
increases. The reason why different species are 
differently affected by passing of equal time should be 
apparent as well: genetic and epigenetic variability. 
Organism modification with time has been mainly 
explained by the production of free radicals as well as 
by immunological theories of aging. However, what we 
still miss is a list of genes responsible for aging; the 
study of these genes would tell us what aging is.  
 
Senectus ipsa morbus est (Old age is in itself a disease), 
ancient romans said. However, the incidence of disease 
decreases in the extreme elderly, when aging expression 
reaches its maximum, whereas progeric syndromes 
associate to disease. Therefore, it is not clear whether 
aging itself is a disease and how it would impact on life 
span in a protected environment. 
 
Our contribution to this field arises from the study of 
p66





























































are  supposed  to damage biological molecules. The  study  of  p66





prolongs life span and protects from a variety of aging-




 Shc is a redox signaller 
 
P66
Shc is a vertebrate protein. It is present in Xenophus, 
Botia Dario and mammals, while it is absent in 
Saccaromyces, Drosophila or Caenorhabditis [1]. P66
Shc 
is one of three isoforms encoded by the ShcA locus [2].  
 
The other two isoforms, p46
Shc and p52
Shc, with 
molecular weights of 46 and 52 KDa respectively, were 
first described as ‘adaptor’ proteins that specifically 
bind to phosphorylated tyrosines on the cytoplasmic 
motif of growth factor receptors.  Upon growth factor 
stimulation, p52
Shc/p46
Shc proteins are rapidly and 
efficiently tyrosine-phosphorylated by all the tyrosine 
kinase receptors tested in three major tyrosine residues, 
and recruit the Grb2-Sos complex on the plasma 
membrane [3]. In turn SOS, through its GEF activity, 
stimulates the conversion of the inactive Ras GDP into 
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mitogen-activated protein kinase (MAPK) cascade. 
Recruitment of the Grb2/Sos complex by p52
Shc/p46
Shc 
and membrane relocalization of Sos are events 
considered sufficient to induce Ras activation [3]. The 
hypothesis that Shc proteins are involved in the 
regulation of Ras is further supported by the finding that 
over-expression of p52
Shc/p46
Shc increases  proliferative 
response and enhances MAP kinase and Fos activation 
upon stimulation with EGF, GM-CSF and PDGF 
[2,4,5]. Notably, the shortest isoforms of Shc appeared 
early in evolution since their orthologues have been 
found in flies and nematods [1]. 
 




share the same amino acid sequence at the C-terminus 
including the Src homologous type two domain (SH2), 
phosphotyrosine binding domain (PTB) responsible for 
the binding to phosphorylated tyrosine, and a region 
highly enriched in glycine and proline residues named 
collagen homologous (CH1) since its homology with 
collagen protein [6]. The peculiarity of p66
Shc is an 
additional CH region (CH2) at its N-terminus [2, 4]. 
 
Despite the high similarity p66
Shc functionally 
differentiates from the other ShcA isoforms. There is no 
indication that p66
Shc activates the Ras signaling 




Shc immediately emerged from 




Shc, is a target of receptor tyrosine kinases (EGFR, 
INSR, PDGFR) and binds the Grb2/SOS complex 
[4,7,8], p66
Shc over-expression, unlike that of 
p52
Shc/p46
Shc, has a negative effect on the Ras-MAPK-
Fos pathway in response to EGF or cytokines in 
lymphocytes [4,9]. In fact, p66
Shc has been shown to 
exert an inhibitory effect on the Erk pathway, which is 
necessary for coordinated actin cytoskeleton poly-
merization [10], and normal IGF-1 responsiveness of 
the MEK/ERK pathway in myoblasts [11]. How p66
Shc 
exerts this negative effect is not clear. It was proposed 
that it acts by competing with p52
Shc for Grb2 binding, 
sequestering the Grb2/Sos complex and therefore 
terminating Ras signaling [11].  
 
Finally, studies on p66
Shc knock down did not 
demonstrated any role for p66
Shc in growth factor 
response or Ras signaling whereas they revealed an 
unexpected function of p66
Shc in regulating intracellular 
redox balance and oxidative stress levels [12]. Indeed, 
compared to WT, the amount of reactive oxygen species 
(ROS) was shown to be decreased in p66
Shc- depleted 
cultivated cells, as revealed by the reduced oxidation of 
ROS sensitive probes as well as by the reduced 
accumulation of endogenous markers of oxidative stress 
[9, 13-17]. Likewise, p66
Shc-/- mice show diminished 
levels of both systemic (isoprostane) and intracellular 
(nytrotyrosines, 8-oxo-dG) oxidative stress [14, 18, 19]. 
 
Mechanisms of p66
 Shc - redox activity regulation 
 
Basically, intracellular ROS levels can be increased by 
three main mechanisms: reducing ROS scavenging, 
increasing membrane oxidases activity, or by mito-
chondrial respiratory chain leakage.  P66
Shc has been 
reported to act through all of them. In fact, p66
Shc 
silencing by RNAi or gene targeting deletion was found 
to increase levels of superoxide dismutases and 
catalases in a variety of cells. In particular, p66
Shc 
appeared to decrease the expression of ROS scavenging 
enzymes through the inhibition of FOXO transcription 
factors [13] (Figure 1). In addition, p66
Shc has been 
proposed to mask the growth factor receptor bound 
protein Grb2 from Sos1, favoring the rac1-specific GEF 
activity of Sos1, rac1 activation and triggering of 
NADPH membrane oxidase ROS production [20] 
(Figure 1).  
 
Finally, a fraction of p66
Shc has been observed within 
the mitochondrial inter-membrane space (IMS) [16]. 
Notably, electrochemical experiments demonstrated that 
the amino terminal portion of p66
Shc contains a redox 
active region able to mediate electron transfer from 
reduced cytochrome c to molecular oxygen, thus 
producing hydrogen peroxide (Figure 1).  
 
As reported, all proteins of the mitochondrial inter-
membrane space are synthesized in the cytosol and are 
then imported into the mitochondria [21]. Most of them 
do not contain any cleavable sequences and are targeted 
to IMS by as yet unidentified import signals. 
 
The import of p66
shc into mitochondrial IMS is not still 
understood at a mechanistic level. However, a 
mechanism that depends on p66
Shc post-translational 
modifications, including serine phosphorylation by 
stress kinases like Jnk-1 and Pkc-B and prolil-
isomerization by Pin-1, has been described, which 
allows p66
Shc increase within the mitochondria during 
apoptosis [22]. A second level of activation of p66
Shc 
mitochondrial function is represented by the effective 
amount of p66
Shc within mitochondrial vesicles. In fact, 
mitochondrial p66
Shc has been observed to associate to a 
high molecular weight complex of about 670 KDa and 
to the mitochondrial chaperon mtHsp70 [23]. Notably, 
treatment of cells with pro-apoptotic stimuli such as 
UVC or H2O2 induces the dissociation of this complex 
and the consequent release of monomeric p66
Shc,
 which 
is then free to react with cytochrome c [23].  
 
 






































Shc half-life increases upon apoptotic 
stimulation in a p53-dependent way, thus linking the 
pro-apoptotic activity of p66
Shc to the p53 pathway [14]. 
 
Function of p66
 Shc – oxidative signal 
 
Regardless of how p66
Shc may shift the intracellular 
redox balance towards oxidation, it appears that p66
Shc 
specifically evolved to increase intracellular ROS 
levels. In this view, different functions have been 
assigned to p66
Shc- produced ROS. Initially it was 
reported that H2O2 produced by p66
Shc within the 
mitochondria induces the opening of the mitochondrial 
permeability transition pore leading to swelling of the 
organelle  [16]. The consequent rupture of mito-
chondrial integrity then triggers the release of various 
proapoptotic mitochondrial factors, including 
















































apoptotic cascade leading to cell death [23]. Indeed, 
p66
Shc-/- cells have been demonstrated to be resistant to 
apoptosis induced by a variety of different signals, 
including ultraviolet radiation, staurosporine, growth 
factor deprivation, calcium ionophore, CD3-CD4 cross-
linking and taxol [9, 12, 23]. Likewise, p66
Shc-/- mice 
were found resistant to apoptosis induced by paraquat, 
hypercholesterolemia, ischemia, angiotensin II, carbon 
tetrachloride and ethanol [12, 15, 16, 18]. Notably, 
p66
Shc deletion in mice was shown to improve 
resistance to hyperglycaemic damage in diabetic model 
of nephropathy and cardiovascular diseases due the 
reduction of apoptosis and cell loss [24, 25]. 
 
Recently, another role for p66
Shc - mediated ROS has 
been described in the regulation of adipogenesis. In 
adipocytes, p66
Shc was demonstrated to be involved in 
insulin-induced gene expression regulation and tri-
   
www.impactaging.com                   505                                             AGING,    June 2009, Vol.1 No.6glyceride accumulation. In fat cells insulin induces serine 
36 specific phosphorylation of p66
Shc thus stimulating 
p66
Shc ROS production, which, in turn, potentiates insulin 
transduction signaling. Indeed, mutants unable to 
translocate to the mitochondria and to produce H2O2 do 
not sustain insulin-dependent signaling and triglyceride 
accumulation when reintroduced in p66
Shc-/- cells  [17]. 
Interestingly, some phosphatases inhibiting insulin 
signaling (e.g. PTEN) are inactivated by oxidation [26]. 
Thus, it appears that p66
Shc -generated ROS play a crucial 
role in regulating insulin signaling and fat development, 
likely through the modulation of these redox-sensitive 
phosphatases. Indeed, p66
Shc-/- mice are protected from 
diet-induced obesity, suggesting that this molecular 
pathway regulates diet-associated fat development [17]. 
But if p66
Shc is able to convert signals from the diet into 






































insulin sensitivity, critically, the process that triggers 
adipogenesis following food intake should stem from the 
integration of both intracellular (mitochondrial ROS 
production) and extracellular (circulating insulin) signals 
[17] (Figure 2). 
 
Notably, p66
 Shc - produced H2O2 might control 
intracellular signaling events also in tissues other than 
fat. In particular, the response of myocytes and 
endothelial cells to glycaemia and ischemia, as well as 
the renewal control of breast stem cells upon hypoxia, 
has been linked to p66
Shc- redox activity [24, 27-29]. 
 
Therefore, p66
Shc behaves like an atypical signal 
transducer that tunes membrane receptor signaling or 
intracellular glucose/oxygen sensing via the regulation 








































leading  to  fat  accumulation.  Food  intake  determines  energetic  substrate  availability  and  insulin
stimulates  intracellular  transduction  pathways  that  regulate  gene  transcription  in  order  to  favor
triglyceride accumulation. P66
Shc‐mediated ROS production is directly boosted by insulin and in turn
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Shc  gene conserved during mammals 
development, in spite of its deleterious effects on life-
span and disease, because of p66
Shc- mediated ROS 
signaling function in fat tissues? 
 
 P66
Shc-/- mice have reduced body weight, due to 
reduced fat mass of both white and brown adipose 
tissues [17]. This leanness is not explainable by changes 
in food intake, intestinal absorption of nutrients or 
locomotor activity. Rather, it may reflect defective 
lipogenesis in adipocytes, as suggested by the reduced 
lipid accumulation of p66
Shc-/- adipocytes transplanted 
into WT recipient mice [17]. However, this 
interpretation of the mechanisms leading to decreased 
fat mass in p66
Shc-/- mice poses the question of how 
energy balance is maintained in the absence of p66
Shc, 
and why energy storage is reduced. As p66
Shc-/- mice 
showed increased basal body temperature and increased 
basal metabolic rate, this suggests that increased 
uncoupled respiration in the fat mitochondria of p66
Shc-
/- mice leads to increased energy expenditure, which 
contributes to resistance to body weight gain  [17]. 
 
Fat has a crucial role in the thermoregulation of 
mammals. It protects from body heat loss (thermo-
insulation) and generates heat for the maintenance of 
body temperature when animals are exposed to cold 
(thermo-genesis). Notably, p66
Shc-/- mice were found to 
be more sensitive to cold due to the reduced thermal 
insulation effect of fat pads [17]. Therefore, adaptation  
to cold as well as optimization of energy storage when 
food is available, both altered in the lean p66
Shc-/- mice, 
have been proposed as possible evolutionary functions 
whose fitness pressure preserves the p66
Shc gene in 
mammals.  
 
These findings of reduced adiposity in p66
Shc-/- mice 
might have important implications for the effect of 
p66
Shc on lifespan. Aging is associated with a 
pathological trait, often associated with obesity 
(metabolic syndrome), which predisposes to diabetes 
and cardiovascular diseases [30-34]. In humans, these 
diseases strongly affect morbidity and mortality, 
especially among the elderly [30, 35]. Oxidative stress 
has been implicated in a number of chronic disease 
states usually grouped under the umbrella of the 
metabolic syndrome [36-42], and it is thought to 
contribute to the aging process [43]. It has been 
hypothesized that the production of free radicals is 
dependent on metabolic rate [44], and that this may 
have an impact on the aging process. In p66
Shc-/- mice, 
like in caloric restriction and FIRKO mice, fat deposits 
are moderately decreased [17, 45], suggesting that 
reduced oxidative stress in p66
Shc-/- mice might increase 
longevity through the direct effect of reduced adiposity.  
Notably, p66
Shc-/- mice are more resistant to diabetes and 
have reduced risk of atherosclerosis and cardiovascular 
damage upon HF-diet [18, 25]. Therefore, the effect of 
p66
Shc on aging might be considered a sort of chronic 
decay like the metabolic syndrome progression, although 
the contribution of the metabolic syndrome to life span is 


























aging  associated  dysfunctions.  P66
Shc/ROS  signals  to
specific  functions  that  improve  fitness  whilst  these  same
functions may increase disease risk chronically (such as obesity
related  disorders)  and  contribute  to  trigger  p66
Shc‐mediated












The life-prolonging action of caloric restriction (CR) 
offers an excellent chance for investigating the 
connection between stress and aging. The anti-aging 
action of CR can be viewed as "nutritional stress," 
because the organism's reduced caloric intake seems to 
be a stimulatory metabolic response for survival. Thus, 
as an omnipotent intervention, CR provides a unique 
opportunity to probe the organism's ability to withstand 
age-related stress as a survival strategy. Recent geriatric 
research has provided sufficient experimental data 
supporting the anti-aging property of CR [46-48]. 
 
 
www.impactaging.com                   507                                             AGING,    June 2009, Vol.1 No.6What kills mammals is a “p66 
Shc   syndrome” 
 
Finally, the study of p66
Shc confirms that very close 
links exist between energetic metabolism, oxidative 
stress and aging. P66
Shc represents a clear example of an 
antagonistic pleiotropic function, which generates both 
beneficial and detrimental phenomena in an organism.  
 
Darwin might say that aging expresses fitness (senectus 
robur est), at least as much as one is able to face illness. 
However, it remains unclear whether aging is also a 
disease or whether life span is regulated by energetic 
metabolism disorders that could eventually result in 
lethal effects or sub-pathological multiple dysfunctions.  
 
In a series of WT and p66
Shc-/- very old moribund mice, 
significant recurring cause of death were not identified. 
Indeed, it is known that in mice as in humans even 
accurate autopsy might often remain "blank", in the 
absence of masses, haemorrhages, abscesses or other 
evident septic conditions. Mice presented only sporadic 
terminal emphysema (mainly in WT mice), occasional 
lymphocytic pneumonia and very rare malignant 
tumors. On the other hand, it is impossible to rule out 
other causes of death, such as cardiac fibrillation or 
acute myocardial infarction, which score negative for 
morphological investigation (unpublished data). 
 
In conclusion, whether aging determines life span 
through diseases or through the acceleration of a fatal 
physiological decline remains puzzling. It is expected 
that further, more intense investigations in the cause of 
death in mammals might contribute to the solution.  
 
P66
Shc story suggests that necessary regulators of 
oxygen and energetic metabolism may be involved both 
in the onset of the acute phase of diseases and in the 
induction of aging related detrimental changes that 
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